ABSTRACT
Introduction
In the current eighth edition of the TNM classification, the definition of tumor diameter in NSCLC was dramatically revised in a measuring method according to radiological and pathological findings.
1,2 A ground glass opacity (GGO) component of a lung nodule on thin-section computed tomography (TSCT) and a lepidic growth component of cancer cells in a pathological specimen are no longer measured as a tumor diameter because these findings reflect noninvasiveness of cancer. A GGO component on TSCT is generally known as a radiological finding basically corresponding to a lepidic growth of cancer cells observed in pathological examination with few exceptions. [3] [4] [5] [6] A solid component of lung nodule on TSCT also corresponds approximately to an invasive lesion, alveolar collapse, or mucin collection in a cancer shown by pathological examination. Many researchers have reported that patients with lung cancer having a GGO component show an encouragingly good prognosis after an appropriate surgical intervention. 4, [6] [7] [8] [9] [10] To determine the T factor by considering only the solid size on TSCT is reasonable for measuring the extent of the cancer invasion and indicating overall survival. However, it includes some issues, namely, the difficulty of measuring solid size on computed tomography (CT) and a good prognosis of the tumor with a GGO component. 11 In this study, we aimed to clarify the influence on patient prognosis of the radiological GGO component in each TNM stage determined by the eighth edition of TNM classification and to offer corroborative evidence of this result with pathological findings determined by the fourth edition of the WHO classification.
Patients and Methods

Patient Selection and Characteristics
According to the objective of this study, we extracted the patient information from the surgical database in our hospital. This study cohort consisted of the 2013 patients with lung cancer who underwent surgery between January 2003 and December 2011 at the National Cancer Center Hospital East, Kashiwa, Japan. Of these patients, we included in the study the 1866 who underwent complete resection by lobectomy with lymph node dissection; did not receive preoperative therapy; had no distant metastasis; and had no low-grade malignancy of carcinoid, mucoepidermoid carcinoma, or adenoid cystic carcinoma according to pathological examination. We excluded the 74 patients who showed undetectable tumors on preoperative CT (n ¼ 1), had no available preoperative TSCT (n ¼ 9), had synchronous lung cancer (n ¼ 62), or had missing data (n ¼ 2). A total of 502 patients in clinical stage IIA to IIIc among the remaining 1792 patients were excluded. The patient extraction flow is summarized in Figure 1 .
Database and Patient Follow-up Policy
In our database, the following clinical and pathological characteristics were recorded: age; sex; history of smoking; preoperative serum carcinoembryonic antigen (CEA) level; maximum tumor size, including GGO component; solid size on TSCT; GGO component;, clinical stage based on the eighth edition TNM classification; and pathological type, including histological subtype, pathological maximum tumor size, invasive size, lepidic component, and pathological stage, also based on the eighth edition TNM classification. We compared only the clinical characteristics among histological and radiological findings (adenocarcinoma with GGO, adenocarcinoma without GGO, and squamous cell carcinoma).
Patients were evaluated at 3-month intervals for the first 2 years and typically at 6-month intervals thereafter on an outpatient basis. Recurrence or survival information was obtained as far as possible for up to 10 years (by a follow-up letter in the case of patients who could not attend regular clinic visits). Recurrence was diagnosed on the basis of compatible physical examination and/or diagnostic imaging findings, and the diagnosis was histologically confirmed when clinically feasible.
Data were collected from our anonymous database of primary lung cancer patients, which was newly revised for this study. The protocol of this study was reviewed and approved by the institutional review board in July 2017 (approval number 2017-066). 
Radiological Evaluation on TSCT
Contrast-enhanced CT scans at 5-to 10-mm collimation of the chest and upper abdomen were performed to assess the clinical staging of all patients with lung cancer. In addition, TSCT images at 1-to 2-mm collimation were reconstructed for evaluating primary tumor size, GGO component, solid size, and other factors. The Xvigor CT system (Toshiba Medical Systems, Tokyo, Japan) was used to perform the CT scans, and CT images were evaluated on a monitor display with a window level of À600 Hounsfield units and a window width of 1800 Hounsfield units. Two observers (K. A. and S. K.), who were unaware of the pathological findings and prognosis, reviewed each lung nodule on preoperative TSCT scans. The solid opacity on TSCT was defined as an area of increased opacification that completely obscured the underlying vascular structures. A GGO was defined as an area of increased hazy density in an area without obscuring the underlying vascular structure. 5, 7 We measured the maximum diameter of the tumor including a GGO and a solid part only in the lung window. The discrepancies in interpretation between the observers were resolved by consensus.
Pathological Evaluation
Surgical specimens were fixed with 10% formalin and embedded in paraffin. Serial 4-mm sections were stained with hematoxylin and eosin and by the Alcian blue-periodic acid-Schiff method for cytoplasmic mucin production. We used elastica van Gieson or Victoria blue-van Gieson staining to visualize elastic fibers and evaluate vascular and pleural invasion for all cases. Lymphatic permeation was basically evaluated with hematoxylin and eosin slides, but we often used D2-40 stain to highlight lymphatic vessels. Histological typing was determined according to the third edition of the WHO classification of cell types, but we reevaluated all cases by using the fourth edition of the WHO classification of tumors of the lung, pleura, thymus, and heart. 12 We measured the invasive size of all adenocarcinomas and reevaluated the histological subtype as follows: adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), lepidic predominant adenocarcinoma, acinar predominant adenocarcinoma, papillary predominant adenocarcinoma, micropapillary predominant adenocarcinoma, and solid predominant adenocarcinoma. 13 
Definition of Overall Survival
The length of overall survival was defined as the interval between the date of surgical intervention and the last follow-up date or death due to any cause. Observations were censored at the last follow-up when the patient was alive or lost to follow-up. The date of data cutoff was October 2017 at our institution.
Statistical Analysis
The main objective of this study was to compare overall survival among three patient subgroups: (1) patients with adenocarcinoma who had a GGO component; (2) other patients with adenocarcinoma; and (3) patients with squamous cell carcinoma. The main patient demographics were compared by using cross tabulations with descriptive statistics according to the clinical stage in the eighth edition of TNM classification.
It has been reported by many researchers that lung adenocarcinoma with a GGO component on the preoperative TSCT generally is slow growing and has a good prognosis after resection. 4, 5, 14 Among the 1012 patients with adenocarcinoma, we examined the distribution of adenocarcinoma subtype (AIS, MIA, invasive lepidic predominant adenocarcinoma, invasive acinar predominant adenocarcinoma, invasive predominant papillary adenocarcinoma, invasive predominant micropapillary adenocarcinoma, and invasive solid predominant adenocarcinoma) in each group by dividing the group on the basis of the presence or absence of a GGO component in the lung nodule on the preoperative TSCT. We mainly compared the proportion of lepidic invasive predominant adenocarcinoma and solid invasive predominant adenocarcinoma at each clinical stage between adenocarcinoma with a GGO component and without a GGO component.
Univariable and multivariable Cox regression analyses were performed to assess the impact of the subgroups on overall survival for only clinical and radiological factors. In the multivariable analyses, we included all the covariate variables listed in Supplementary Table 1 after checking the correlation among them to avoid multicollinearity. The regression analyses were planned to be performed in a complete analysis set, which removed all patients with missing data in the covariate variables from the data set.
Survival curves were estimated by the Kaplan-Meier method according to the three subgroups, clinical stage, and histological types. Their comparisons were performed by using the log-rank test. All statistical analyses were performed with JMP 10 statistical software (version 10.0.2. 64-bit edition, SAS Institute Inc., Cary, NC), GraphPad Prism (Prism for Windows, version 5.02, GraphPad Software, Inc., La Jolla, CA), and SAS release 9.4 (64-bit edition; SAS Institute, Cary, NC).
Results
The total number of patients in this cohort was 1290, and the median follow-up period of all censored cases was 8.6 years. Patient clinical and pathological characteristics are summarized in Table 1 , and IB were 152 (12%), 435 (34%), 413 (32%), and 269 (21%), respectively. Adenocarcinomas were predominantly found in 1012 of the 1290 patients (78%). Among them, 29 patients were classified as having AIS, and 94 patients were classified as having MIA. The number of patients with invasive adenocarcinoma was 867. These were divided into each histological subtype of adenocarcinoma (231 with invasive lepidic predominant adenocarcinoma, 128 with invasive acinar predominant adenocarcinoma, 325 with invasive papillary predominant adenocarcinoma, 14 with invasive micropapillary predominant adenocarcinoma, and 169 with invasive solid predominant adenocarcinoma). In terms of variants of adenocarcinoma, there were two invasive mucinous adenocarcinomas, 17 mixed invasive and nonmucinous adenocarcinomas, one colloid adenocarcinoma, and two fetal adenocarcinomas. The number of patients with squamous cell carcinoma was 195 (15%), and the number with large cell carcinoma was 26 (2%). There were 22 patients with large cell neuroendocrine carcinoma (2%) and 23 with adenosquamous carcinoma (2%). Pleomorphic carcinoma was diagnosed in 11 patients (1%). The average maximum tumor diameter including the lepidic component plus or minus the SD (measured according to pathological examination) was 25 plus or minus 10 mm. The pathological invasive size was 19 plus or minus 11 mm. The lepidic component was recognized in 778 of the 1012 patients with adenocarcinoma (77%). The number Figure 2 shows overall survival curves according to the clinical stage and distinct differences between clinical stages. The 5-year survival rates of clinical stages 0, IA1, IA2, IA3, and IB were 100%, 95%, 84%, 76%, and 65%, respectively. Figure 3D shows the overall survival of the patients with adenocarcinoma with a GGO component, adenocarcinoma without a GGO component, squamous cell carcinoma, and other types in clinical stage IA2. In clinical stage IA2, the overall survival of patients with adenocarcinoma with a GGO component was considerably better than that of patients in the other groups. A comparison of clinical stage IA3 with IA2 showed similar results (Fig. 3E) . However, there was no difference between adenocarcinoma with a GGO component, adenocarcinoma without GGO component, and squamous cell carcinoma in the group with clinical stage IB ( Figure 3F) . Tables 2 to 4 show patients' clinical characteristics  according to clinical stage IA2 (see Table 2 ), clinical stage IA3 (see Table 3 ), and clinical stage IB (see Table 4 ). The patients with squamous cell carcinoma were older and included a larger number of smokers than did the other groups of patients at each stage. The group of patients with adenocarcinoma with a GGO component contained a larger number of women and never-smokers than the other groups of patients at each stage. Tables 5 and 6 show the distribution of histological subtypes (AIS, MIA, invasive lepidic predominant adenocarcinoma, invasive acinar predominant adenocarcinoma, invasive papillary predominant adenocarcinoma, invasive micropapillary predominant adenocarcinoma, and invasive solid predominant adenocarcinoma) at each clinical stage of adenocarcinoma with a GGO component (see Table 5 ) and adenocarcinoma without a GGO component (see Table 6 ). In clinical stage 0 to IA3, the patients showing AIS, MIA, and invasive lepidic predominant adenocarcinoma pathologically accounted for about 50% of the total number of patients with adenocarcinoma having a GGO component (stage 0, 16 of 21; stage IA1, 113 of 143; stage IA2, 80 of 157; and stage IA3, 45 of 94). The remaining adenocarcinomas with a GGO component on TSCT were invasive adenocarcinoma except for lepidic predominant adenocarcinoma pathologically (see Table 5 ). Seven of the 38 patients with adenocarcinoma having a GGO component showed pathological features of invasive solid predominant adenocarcinoma in clinical stage IB (19%). With respect to adenocarcinoma without GGO, most of the patients were in clinical stage IA2 to IB, and the distribution of the histological subtype was very similar at each clinical stage. In particular, invasive acinar and solid predominant adenocarcinomas were more common in adenocarcinoma without a GGO component. In clinical stage IB, the distribution of the histological subtype was very similar between adenocarcinoma with and without a GGO component.
Supplementary Table 1 shows the results of univariate and multivariate Cox regression analyses to identify clinical and radiological factors related to overall survival. This result indicated that being of a young age, being female, testing negative for CEA, and having a diagnosis of adenocarcinoma with a GGO component were independent clinical and radiological factors implying good prognosis. Supplementary Figures 1 to 3 show overall survival curves of clinical stage according to the histological types, in particular, by dividing the group of patients with adenocarcinoma into patients with adenocarcinoma with a lepidic component and patients without any lepidic component. Supplementary Figures 4 to 6 show overall survival curves of pathological stage according to the histological types, in particular, by dividing the group of patients with adenocarcinoma into patients with adenocarcinoma with any lepidic component and patients without any lepidic component.. Supplementary Figure 1 shows the significant difference in overall survival between the patients with adenocarcinoma with any lepidic component and without any lepidic component (p < 0.01). The same results were shown in clinical stage IA3 and IB (see Supplementary Figs. 2 and 3) . However, when they were grouped by pathological stage, overall survival curves of patients with adenocarcinoma with or without any lepidic component appeared to be well divided, but there was no significant difference (see Supplementary Figs. 4 and 5 ). There was no difference between adenocarcinoma with any lepidic component, adenocarcinoma without any lepidic component, and squamous cell carcinoma in the group with pathological stage IB group (see Supplementary Fig. 6 ).
Discussion
The revised T descriptor in the eighth edition TNM classification is based on the invasive size according to radiological or pathological findings; we considered this measurement to be feasible, and we also reported that each overall survival curve was well separated from the other. 15 This consideration is based on the Union for International Cancer Control policy that tumors should be measured only in the invasive area of a cancer. It is well known that lung cancer including a well-defined GGO component on TSCT is mostly adenocarcinoma and has a good prognosis. 4, 7, [16] [17] [18] The GGO component in a lung nodule on TSCT corresponds pathologically to alveolar septal thickness and contained air in the alveoli, namely, to lepidic growth preserving the existing alveolar structure of the cancer cells. A lepidic growth pattern represents cancer cells growing with the existing alveolar structure and implies noninvasiveness. 19, 20 The lung cancer containing much of this histological subtype implies a well-differentiated and less-invasive nature. These facts were previously reported by Noguchi et al. 21 The solid component in the lung cancer containing a GGO on TSCT mostly corresponds pathologically to alveolar collapse or fibrosis. In the case of the same solid size in the lung cancer on TSCT, the poorly differentiated component in the lung cancer with GGO was considerably smaller than that without a GGO (data not shown).
Actually, the approximately 50% of patients with adenocarcinoma with a GGO component in clinical stage IA (solid size <3 cm) demonstrated lung adenocarcinoma with a dominant lepidic component, and the occurrence was higher than in that of adenocarcinoma without a GGO component (Tables 5 and 6 ). In addition, the occurrence of lung adenocarcinoma with a dominant solid component in patients with lung adenocarcinoma without a GGO component was higher only than that in lung adenocarcinoma with a GGO component in clinical stage IA. These histological findings led to a major difference in patient survival between lung cancer with a GGO component and lung cancer without a GGO component. However, the distribution of histological subtype and prognosis in lung adenocarcinoma with a GGO component became similar to those in lung adenocarcinoma without a GGO component in clinical stage IB (solid size !3 cm). Both survival curves also became increasingly similar to the survival curve of patients with squamous cell carcinoma. Hwang et al. reported that the part-solid GGN group showed longer (14) 42 (23) 21 (30) Ad, adenocarcinoma; GGO, ground glass opacity; Sq, squamous cell carcinoma; CEA, carcinoembryonic antigen. overall survival than did the solid nodule group when the diameter of the solid part was 2 cm or less. 22 In our study, overall survival of clinical stage IA3 was clearly discriminated by the presence or absence of a GGO component in lung tumor on preoperative TSCT. The adenocarcinoma with GGO group with a solid part larger than 3 cm was not different from the other group. This difference may have been caused by a difference in the determined cutoff value.
The occurrence of a predominant subtype of solid adenocarcinoma with mucin in patients with adenocarcinoma without a GGO component was higher than that in patients with adenocarcinoma with a GGO component in clinical stage IA. However, in clinical stage IB, the occurrence of this subtype in adenocarcinoma with a GGO component increased to a level similar to that in adenocarcinoma without a GGO component. A solid adenocarcinoma component correlates with nodal involvement, vessel invasion, and pleural invasion and leads to poor prognosis. 23, 24 In partly solid nodules, the solid portion on TSCT mainly corresponds to pathological findings of alveolar collapse and/or fibrosis; however, in lung nodules without a GGO component, a solid part on TSCT corresponds mainly to invasive subtypes (acinar, papillary, micropapillary, and solid subtypes). A collapse and/or fibrosis has sometimes been identified in lung nodules without a GGO component, but the size of a collapse and/or fibrosis in a lung adenocarcinoma without a GGO component was significantly smaller than that in a lung adenocarcinoma with a GGO component (data not shown). Therefore, these results may cause the difference in overall survival between these adenocarcinomas.
Noguchi et al. proposed the histological Noguchi classification in a small adenocarcinoma in 1995. 21 They reported that a stepwise progression of a lung adenocarcinoma was an important concept for cancer growth in lung adenocarcinoma, and early-stage adenocarcinomas of the lung were classified into two groups, namely, the lepidic growth pattern and destructive growth pattern of existing alveolar structures. The former types, which are known as Noguchi types A, B, and C, were related to the stepwise progression of peripheral-type adenocarcinoma and indicated a relatively good prognosis. The latter types, which are known as Noguchi types D, E, and F, were related to moderate or poor differentiation and indicated a generally poor prognosis. The pathological characteristics were closely associated with radiological findings such as lung nodules with or without a GGO component and linked to patients' outcome. This was supported by the results shown in Figure 3 . Additionally, Supplementary  Figures 1 to 3 showed a worse prognosis of adenocarcinoma without any lepidic component compared with that of the other in each clinical stage. This indicates that adenocarcinoma without any lepidic component will be highly malignant biologically. However, when they were grouped by pathological stage, the survival curve of adenocarcinoma with any lepidic component in the tumor pathologically did not show significant difference from that without any lepidic component in each pathological stage. This suggests that pathological staging will be able to distinguish prognostic group better than clinical staging by using the other factors. These radiological findings should be evaluated by TSCT. However, the reproducibility of radiological evaluation is always a major concern in this field. We sometimes encounter difficulty in evaluation of the ground glass appearance on TSCT, but we need to become familiar with these radiological findings of adenocarcinoma on TSCT as experts in the field of thoracic malignancy.
Conclusion
The current version of the T descriptor was relatively reliable, but this study showed that patients with lung cancer in the same staging group included a subgroup of patients who presented a different outcome. We propose a clinical T classification considering the presence or absence of a GGO component in the next version of the TNM classification. This would lead to more accurate prognoses for patients with a lung cancer tumor less than 3 cm in invasive diameter.
